tradingkey.logo

Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema

ReutersOct 8, 2025 12:18 PM

- Astria Therapeutics Inc ATXS.O:

  • ASTRIA THERAPEUTICS INITIATES THE PHASE 3 ORBIT-EXPANSE LONG-TERM TRIAL OF NAVENIBART IN PEOPLE WITH HEREDITARY ANGIOEDEMA

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI